• Faraz Khan Luni, Nath Zungsontiporn, Talha Farid, Sonia Ali Malik, Sobia Khan, James Daniels, Richard Wu, Mark S Link, and Jose A Joglar.
• Department of Cardiology, UT Southwestern Medical Center, Dallas, Texas.
• J. Cardiovasc. Electrophysiol. 2019 Jun 1; 30 (6): 886-895.

IntroductionCatheter ablation of ventricular tachycardia (VT) can be an effective therapy to reduce VT burden, but often it is limited by the potential for hemodynamic instability. Percutaneous left ventricular assist devices (pLVADs) have been used to maintain hemodynamic support during VT ablation but the evidence regarding its clinical impact has been inconclusive.Methods And ResultsWe sought to assess the clinical impact of pLVAD when used in VT ablation by conducting a meta-analysis of the current evidence. We searched Pubmed and found nine observational studies that compared clinical outcomes of VT ablation in patients with pLVAD support to controls with no pLVAD support. The pooled data did not show a significant difference in mortality between both groups, nor a difference in acute procedural success or in recurrence of VT. There was also no difference in the number of patients receiving a cardiac transplant or being enrolled in the transplant list. Although there was no difference in the ablation time between the groups, patients in the pLVAD group had a longer total procedural time and more procedure-related adverse effects.ConclusionThis meta-analysis did not show clinical benefits from using pLVAD support during VT ablation, whereas it was associated with longer procedure times and more complications. This study was, however, limited by the observational nature of the data. In view of these data, the risk and benefit of pLVAD support during VT ablation should be considered on an individual basis.© 2019 Wiley Periodicals, Inc.

27 keywords...

hide…